Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2019-003076-39 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a Phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| efgartigimod PH20 SC | Experimental | patients receiving efgartigimod PH20 SC in both stage A as stage B |
|
| Placebo | Placebo Comparator | patients receiving efgartigimod PH20 SC during stage A and receiving placebo in stage B |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| efgartigimod PH20 SC in stage B | Biological | Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC |
|
| Measure | Description | Time Frame |
|---|---|---|
| Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) | Up to 12 weeks during the open-label stage A | |
| Stage B: Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline | Up to 48 weeks during the randomized placebo-controlled stage B |
| Measure | Description | Time Frame |
|---|---|---|
| Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI) | Up to 12 weeks during the open-label stage A | |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Adjusted INCAT Score | Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability. |
Not provided
Inclusion Criteria:
Ability to understand the requirements of the trial, provide written informed consent (include consent for the use and disclosure of research-related health information), willingness and ability to comply with the trial protocol procedures (including required trial visits)
Male or female patient aged 18 years or older, at the time of signing the informed consent.
Diagnosed with probable or definite CIDP according to criteria of the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS 2010), progressing or relapsing forms.
CIDP Disease Activity Status (CDAS) score ≥2 at screening.
INCAT score ≥2 at the first run-in visit (for patients entering run-in) or stage A baseline (for treatment-naïve patients with documented evidence for worsening on the total adjusted INCAT disability score within 3 months prior to screening). Patients with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score; for patients with an INCAT score of ≥3 at trial entry, there are no specific requirements for arm or leg scores.
Fulfilling any of the following treatment conditions:
Women of childbearing potential who have a negative pregnancy test at screening and a negative urine pregnancy test up to Stage A baseline.
Women of childbearing potential must use an acceptable method of contraception from signing the ICF until the date of the last dose of IMP
Exclusion Criteria:
Pure sensory atypical CIDP (EFNS/PNS definition).
Polyneuropathy of other causes, including the following: Multifocal motor neuropathy; Monoclonal gammopathy of uncertain significance with anti-myelin associated, glycoprotein immunoglobulin M (IgM) antibodies; Hereditary demyelinating neuropathy; Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy.
Any other disease that could better explain the patient's signs and symptoms.
Any history of myelopathy or evidence of central demyelination.
Current or past history (within 12 months of screening) of alcohol, drug or medication abuse.
Severe psychiatric disorder (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation that in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol.
Patients with clinically significant active or chronic uncontrolled bacterial, viral, or fungal infection at screening, including patients who test positive for an active viral infection at screening with: Active Hepatitis B Virus (HBV): serologic panel test results indicative of an active (acute or chronic) infection; Active Hepatitis C Virus (HCV): serology positive for HCV-Ab; Human Immunodeficiency Virus (HIV) positive serology associated with an Acquired Immune Deficiency Syndrome (AIDS)-defining condition or with a cluster of differentiation 4 (CD4) count ≤200 cells/mm3.
Total IgG level <6 g/L at screening.
Treatment with the following: Within 3 months (or 5 half-lives of the drug, whichever is longer) before screening: plasma exchange or immunoadsorption, any concomitant Fc-containing therapeutic agents or other biological, or any other investigational product; Within 6 months before screening: rituximab, alemtuzumab, any other monoclonal antibody, cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, methotrexate, azathioprine, mycophenolate, any other immunomodulating or immunosuppressive medications, and oral daily corticosteroids >10 mg/day. Note: Patients using IVIg, SCIg, pulsed corticosteroids, and oral daily corticosteroids ≤10 mg/day can be included.
Patients who (intend to) use prohibited medications and therapies (see protocol) during the trial.
Pregnant and lactating women and those intending to become pregnant during the trial or within 90 days after last IMP administration.
Patients with any other known autoimmune disease that, in the opinion of the investigator, would interfere with an accurate assessment of clinical symptoms of CIDP.
Patients who received a live-attenuated vaccine fewer than 28 days before screening. Receiving an inactivated, sub-unit, polysaccharide, or conjugate vaccine any time before screening is not exclusionary.
Patients who have a history of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first IMP administration. Patients with the following cancer can be included anytime: Adequately treated basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, or Incidental histological finding of Prostate cancer (TNM [tumor, nodes, and metastases classification] stage T1a or T1b).
Patients who previously participated in a trial with efgartigimod and have received at least one administration of IMP.
Patients with known medical history of hypersensitivity to any of the ingredients of IMP.
Patients with clinical evidence of other significant serious disease or patients who underwent a recent or have a planned major surgery, or any other reason which could confound the results of the trial or put the patient at undue risk.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigator site 0010065 | Birmingham | Alabama | 35233-2110 | United States | ||
| Investigator site 0010013 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39304241 | Derived | Allen JA, Lin J, Basta I, Dysgaard T, Eggers C, Guptill JT, Gwathmey KG, Hewamadduma C, Hofman E, Hussain YM, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu MA, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis RA, van Doorn PA; ADHERE Study Group. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2024 Oct;23(10):1013-1024. doi: 10.1016/S1474-4422(24)00309-0. | |
| 38205888 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
ARGX-113-1802 enrolled a broad and global (North America, Asia, Europe, and the rest of the world [ROW]) population of treatment-naïve participants and participants who were previously treated for CIDP (corticosteroids, IVIg, or SCIg) with confirmed, active disease and a wide range of disease severity.
A total of 322 participants received efgartigimod PH20 SC in Stage A, and 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Stage A: Efgartigimod PH20 SC | Participants receiving efgartigimod PH20 SC in Stage A |
| FG001 | Stage B: Efgartigimod PH20 SC | Participants who completed stage A and received efgartigimod PH20 SC in stage B |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Stage A |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Oct 12, 2022 | May 2, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo in stage B | Other | Stage A: N/A, stage B: placebo |
|
| Up to 12 weeks during the open-label stage A |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Medical Research Council (MRC) Sum Score | The Medical Research Council (MRC) Sum scores range from 0 to 60 with a lower score indicating greater muscle weakness. | Up to 12 weeks during the open-label stage A |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in I-RODS Disability Scores | The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability. | Up to 12 weeks during the open-label stage A |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in TUG Score | The Timed Up and Go (TUG) score is calculated as the number of seconds needed to complete a series of actions. The longer time needed to complete this test (expressed in seconds) indicates lower mobility. | Up to 12 weeks during the open-label stage A |
| Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Mean Grip Strength | This is measured with a handheld device called a vigometer | Up to 12 weeks during the open-label stage A |
| Stage A: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events | Treatment-emergent (serious) AEs expressed in number of events/100 PYFU (participant years of follow-up) | Up to 12 weeks during the open-label stage A |
| Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | Up to 13 weeks during the open-label stage A (12 weeks + optional 1 additional week to confirm evidence of clinical improvement (ECI)) |
| Stage A: Percent Changes From Stage A Baseline of Serum IgG Levels Over Time | Up to 13 weeks during the open-label stage A (12 weeks + optional 1 additional week to confirm evidence of clinical improvement (ECI)) |
| Stage A: Number of Participants With Binding Antidrug Antibodies (ADA) Towards Efgartigimod or Antibodies (Ab) Against rHuPH20 and Neutralizing Antibodies (NAb) Against Efgartigimod and/or rHuPH20 | Up to 12 weeks during the open-label stage A |
| Stage A: Changes From Stage A Baseline to Last Assessment in Stage A, in EQ-5D-5L Visual Analog Scale (VAS) Over Time | Scores range from 0-100 with 100 indicating the best health state. Therefore, positive changes indicate higher health-related quality of life reported by the patient. | Up to 12 weeks during the open-label stage A |
| Stage B: Time to CIDP Disease Progression | Time to chronic inflammatory demyelinating polyneuropathy (CIDP) disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in Adjusted INCAT Score | Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in MRC Sum Score | The Medical Research Council (MRC) Sum scores range from 0 to 60 with a lower score indicating greater muscle weakness. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in 24-item I-RODS Disability Score | The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in TUG Score | The Timed Up and Go (TUG) score is calculated as the number of seconds needed to complete a series of actions. The longer time needed to complete this test (expressed in seconds) indicates lower mobility. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in Mean Grip Strength | This is measured with a handheld device called a vigometer | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Time to 10% Decrease in the 24-item I-RODS | The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events | Treatment-emergent (serious) AEs expressed in number of events/100 PYFU (participant years of follow-up) | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Pre-dosing Efgartigimod Serum Concentrations Over Time | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Percent Changes of Serum IgG Levels Over Time | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Number of Participants With Binding Antidrug Antibodies (ADA) Towards Efgartigimod or Antibodies (Ab) Against rHuPH20 and Neutralizing Antibodies (NAb) Against Efgartigimod and/or rHuPH20 | Up to 48 weeks during the randomized placebo-controlled stage B |
| Stage B: Changes From Stage B Baseline to Last Assessment in Stage B, in EQ-5D-5L Visual Analog Scale (VAS) Over Time | Scores range from 0-100 with 100 indicating the best health state. Therefore, positive changes indicate higher health-related quality of life reported by the patient. | Up to 48 weeks during the randomized placebo-controlled stage B |
| Phoenix |
| Arizona |
| 85018 |
| United States |
| Investigator site 0010055 | Scottsdale | Arizona | 85028 | United States |
| Investigator Site 0010032 | Carlsbad | California | 92011 | United States |
| Investigator site 0010004 | Orange | California | 92868 | United States |
| Investigator site 0010190 | Pomona | California | 91767-2009 | United States |
| Investigator site 0010160 | Rancho Mirage | California | 92270 | United States |
| Investigator site 0010071 | San Francisco | California | 94109 | United States |
| Investigator site 0010057 | Centennial | Colorado | 80112 | United States |
| Investigator site 0010026 | New Haven | Connecticut | 06520 | United States |
| Investigator site 0010072 | Boca Raton | Florida | 33487 | United States |
| Investigator site 0010144 | Coral Springs | Florida | 33067-4640 | United States |
| Investigator site 0010023 | Jacksonville | Florida | 32209 | United States |
| Investigator Site 0010068 | Maitland | Florida | 32751 | United States |
| Investigator site 0010059 | Miami | Florida | 33136 | United States |
| Investigator site 0010050 | Orlando | Florida | 32806 | United States |
| Investigator site 0010172 | Ormond Beach | Florida | 32174-3102 | United States |
| Investigator site 0010006 | Tampa | Florida | 33612 | United States |
| Investigator site 0010125 | Augusta | Georgia | 30912-3125 | United States |
| Investigator site 0010011 | Iowa City | Iowa | 52242 | United States |
| Investigator site 0010015 | Fairway | Kansas | 66205 | United States |
| Investigator site 0010147 | Lexington | Kentucky | 40536 | United States |
| Investigator site 0010014 | Detroit | Michigan | 48201 | United States |
| Investigator site 0010063 | East Lansing | Michigan | 48824 | United States |
| Investigator site 0010052 | Minneapolis | Minnesota | 55455-4800 | United States |
| Investigator site 0010028 | Columbia | Missouri | 65212 | United States |
| Investigator site 0010070 | New Brunswick | New Jersey | 08550 | United States |
| Investigator site 0010069 | New York | New York | 06511 | United States |
| Investigator site 0010168 | New York | New York | 10001 | United States |
| Investigator site 0010191 | New York | New York | 10021 | United States |
| Investigator site 0010074 | New York | New York | 10032 | United States |
| Investigator site 0010075 | Patchogue | New York | 11772 | United States |
| Investigator site 0010003 | Chapel Hill | North Carolina | 27517 | United States |
| Investigator site 0010077 | Durham | North Carolina | 27710 | United States |
| Investigator site 0010051 | Cincinnati | Ohio | 45267-0525 | United States |
| Investigator site 0010064 | Columbus | Ohio | 43210 | United States |
| Investigator site 0010047 | Philadelphia | Pennsylvania | 15213 | United States |
| Investigator site 0010007 | Philadelphia | Pennsylvania | 19104 | United States |
| Investigator site 0010067 | Pittsburgh | Pennsylvania | 15123 | United States |
| Investigator site 0010066 | Austin | Texas | 78756 | United States |
| Investigator site 0010026 | Houston | Texas | 77055-7421 | United States |
| Investigator site 0010009 | San Antonio | Texas | 78229 | United States |
| Investigator site 0010076 | Burlington | Vermont | 05401 | United States |
| Investigator site 0010007 | Charlottesville | Virginia | 22903 | United States |
| Investigator site 0010061 | Richmond | Virginia | 23298 | United States |
| Investigator site 0430009 | Graz | 8036 | Austria |
| Investigator site 0430007 | Innsbruck | 6020 | Austria |
| Investigator site 0430008 | Linz | 4021 | Austria |
| Investigator site 0430006 | Salzburg | 5020 | Austria |
| Investigator site 0430005 | Vienna | 1090 | Austria |
| Investigator site 0320017 | Brussels | 1090 | Belgium |
| Investigator site 0320019 | Brussels | 1090 | Belgium |
| Investigator site 0320016 | Edegem | 2650 | Belgium |
| Investigator site 0320009 | Leuven | 3000 | Belgium |
| Investigator site 0320024 | Liège | 4000 | Belgium |
| Investigator site 0320022 | Woluwe-Saint-Lambert | 1200 | Belgium |
| Investigator site 3590007 | Pleven | 5800 | Bulgaria |
| Investigator site 3590008 | Sofia | 1113 | Bulgaria |
| Investigator site 3590009 | Sofia | 1431 | Bulgaria |
| Investigator site 3590005 | Sofia | 1680 | Bulgaria |
| Investigator site 0860033 | Beijing | 100053 | China |
| Investigator site 0860030 | Changchun | China |
| Investigator site 0860041 | Changsha | 410008 | China |
| Investigator site 0860036 | Chengdu | China |
| Investigator site 0860049 | Chifeng | 024000 | China |
| Investigator site 0860038 | Fuzhou | 350001 | China |
| Investigator site 0860050 | Guanzhou | 510120 | China |
| Investigator site 0860032 | Guanzhou | 510515 | China |
| Investigator site 0860045 | Guiyang | 550000 | China |
| Investigator site 0860046 | Hangzhou | China |
| Investigator site 0860035 | Hanzhou | 310003 | China |
| Investigator site 0860031 | Jinan | 2500012 | China |
| Investigator site 0860063 | Jining | China |
| Investigator site 0860044 | Nanchang | 330088 | China |
| Investigator Site 0860040 | Nanchang | China |
| Investigator site 0860051 | Nanchang | China |
| Investigator site 0860043 | Nanjing | 210001 | China |
| Investigator site 0860043 | Nanjing | China |
| Investigator site 0860047 | Shanghai | 200090 | China |
| Investigator site 0860028 | Shanghai | China |
| Investigator site 0860052 | Shanghai | China |
| Investigator site 0860042 | Taiyuan | 030001 | China |
| Investigator site 0860029 | Wuhan | 430040 | China |
| Investigator site 0860034 | Wuhan | 430060 | China |
| Investigator site 0860048 | Xi'an | 710038 | China |
| Investigator site 0860037 | Xi'an | 710075 | China |
| Investigator site 0860054 | Xiangyang | 712000 | China |
| Investigator site 4200010 | Hradec Králové | 500-03 | Czechia |
| Investigator site 0450002 | Aarhus | 8200 | Denmark |
| Investigator site 0450001 | Copenhagen | 2100 | Denmark |
| Investigator site 0450003 | Odense | 5000 | Denmark |
| Investigator site 0330034 | Angers | 49033 | France |
| Investigator site 0330013 | Bordeaux | 33076 | France |
| Investigator site 0330033 | Clermont-Ferrand | 63003 | France |
| Investigator site 0330025 | Garches | 92380 | France |
| Investigator site 0330023 | Le Kremlin-Bicêtre | 94275 | France |
| Investigator site 0330024 | Limoges | 87042 | France |
| Investigator site 0330022 | Nantes | 44093 | France |
| Investigator site 0330021 | Nice | 06202 | France |
| Investigator site 0330035 | Paris | 75013 | France |
| Investigator site 0330020 | Strasbourg | 67098 | France |
| Investigator site 9950020 | Kutaisi | 4600 | Georgia |
| Investigator site 9950005 | Tbilisi | 0112 | Georgia |
| Investigator Site 9950002 | Tbilisi | Georgia |
| Investigator Site 9950003 | Tbilisi | Georgia |
| Investigator Site 9950004 | Tbilisi | Georgia |
| Investigator site 0490018 | Berlin | 10117 | Germany |
| Investigator site 0490017 | Berlin | Germany |
| Investigator site 0490044 | Bochum | 37075 | Germany |
| Investigator site 0490013 | Cologne | 50937 | Germany |
| Investigator site 0490045 | Essen | 45147 | Germany |
| Investigator site 0490021 | Göttingen | Germany |
| Investigator site 0490014 | Hanover | Germany |
| Investigator site 0490016 | Kiel | 24105 | Germany |
| Investigator site 0490020 | Leipzig | Germany |
| Investigator site 0490019 | Potsdam | 14471 | Germany |
| Investigator site 0490015 | Regensburg | 93053 | Germany |
| Investigator site 0360017 | Budapest | 1121 | Hungary |
| Investigator site 0360018 | Kistarcsa | 1121 | Hungary |
| Investigator site 9720006 | Holon | 58100 | Israel |
| Investigator site 9720005 | Ramat Gan | 52621 | Israel |
| Investigator site 9720004 | Tel Aviv | 6423906 | Israel |
| Investigator site 0390022 | Brescia | Italy |
| Investigator site 0390029 | Florence | Italy |
| Investigator site 0390024 | Genova | Italy |
| Investigator site 0390027 | Messina | 98125 | Italy |
| Investigator site 0390003 | Milan | Italy |
| Investigator site 0390026 | Milan | Italy |
| Investigator site 0390007 | Naples | 80131 | Italy |
| Investigator site 0390023 | Pisa | Italy |
| Investigator site 0390008 | Roma | Italy |
| Investigator site 0390028 | Siena | Italy |
| Investigator site 0390042 | Torino | 10126 | Italy |
| Investigator site 0810035 | Bunkyō City | 113-8582 | Japan |
| Investigator site 0810002 | Chiba | Japan |
| Investigator site 0810034 | Chūōku | Japan |
| Investigator site 0810030 | Fuchū | 183-0042 | Japan |
| Investigator site 0810031 | Fukuoka | 812-8582 | Japan |
| Investigator site 0810065 | Ginowan | 901-214 | Japan |
| Investigator site 0810066 | Hakodate | 041-0821 | Japan |
| Investigator site 0810058 | Hiroshima | 730-0011 | Japan |
| Investigator site 0810029 | Kawaguchi | Japan |
| Investigator site 0810062 | Kawasaki | 2016-0015 | Japan |
| Investigator site 0810026 | Kodaira | Japan |
| Investigator site 0810061 | Kyoto | 616-8255 | Japan |
| Investigator site 0810027 | Mibu | Japan |
| Investigator site 0810032 | Nagoya | Japan |
| Investigator site 0810003 | Osaka | 565-0871 | Japan |
| Investigator site 0810007 | Osaka | Japan |
| Investigator site 0810028 | Sagamihara | Japan |
| Investigator site 0810033 | Sapporo | 0608638 | Japan |
| Investigator site 0810037 | Shinjuku-Ku | 160-8582 | Japan |
| Investigator site 0810063 | Suita | 565-0871 | Japan |
| Investigator site 0810036 | tabashi City | 173-8606 | Japan |
| Investigator site 0810064 | Tokushima | 770-0042 | Japan |
| Investigator site 0810060 | Yokohama | 236-0004 | Japan |
| Investigator site 3710001 | Riga | 1038 | Latvia |
| Investigator site 0310010 | Amsterdam | 1105 | Netherlands |
| Investigator site 0310011 | Rotterdam | Netherlands |
| Investigator site 0480019 | Bialystok | 15-402 | Poland |
| Investigator site 0480023 | Katowice | 40-650 | Poland |
| Investigator site 0480017 | Krakow | 30-539 | Poland |
| Investigator site 0480024 | Krakow | 31-202 | Poland |
| Investigator site 0480020 | Lodz | 90-324 | Poland |
| Investigator site 0480018 | Lublin | 20-090 | Poland |
| Investigator site 0480022 | Warsaw | Poland |
| Investigation site 0400002 | Brasov | 500299 | Romania |
| Investigator site 0400001 | Bucharest | 011302 | Romania |
| Investigator site 0400004 | Constanța | 900591 | Romania |
| Investigator site 0400003 | Timișoara | 300723 | Romania |
| Investigator site 0070017 | Kazan' | 420021 | Russia |
| Investigator site 0070023 | Kazan' | 420097 | Russia |
| Investigator site 0070016 | Moscow | 117186 | Russia |
| Investigator site 0070020 | Moscow | 117186 | Russia |
| Investigator site 0070018 | Perm | Russia |
| Investigator site 0070019 | Rostov-on-Don | 344022 | Russia |
| Investigator site 0070014 | Saint Petersburg | 194354 | Russia |
| Investigator site 0070021 | Saransk | 430032 | Russia |
| Investigator site 3810001 | Belgrade | 11000 | Serbia |
| Investigator site 3810003 | Belgrade | 11000 | Serbia |
| Investigator site 3810004 | Kragujevac | Serbia |
| Investigator site 0340020 | Alicante | 03010 | Spain |
| Investigator site 0340021 | Badalona | 08041 | Spain |
| Investigator site 0340038 | Barcelona | Spain |
| Investigator site 0340019 | Córdoba | 14011 | Spain |
| Investigator site 0340017 | Madrid | 28007 | Spain |
| Investigator site 0340018 | Madrid | 28040 | Spain |
| Investigator site 0340016 | Seville | 41013 | Spain |
| Investigator site 8860014 | Kaohsiung City | Taiwan |
| Investigator site 8860015 | Taichung | Taiwan |
| Investigator site 8860013 | Tainan | Taiwan |
| Investigator site 8860011 | Taipei | Taiwan |
| Investigator site 8860012 | Taipei | Taiwan |
| Investigator site 8860016 | Taipei | Taiwan |
| Investigator site 8860017 | Taoyuan | Taiwan |
| Investigator site 0900025 | Bursa | Turkey (Türkiye) |
| Investigator site 0900023 | Istanbul | Turkey (Türkiye) |
| Investigator site 0900021 | Izmir | Turkey (Türkiye) |
| Investigator site 0900022 | Samsun | Turkey (Türkiye) |
| Investigator site 0900024 | Sarıçam | Turkey (Türkiye) |
| Investigator site 3800012 | Dnipro | 49069 | Ukraine |
| Investigator site 3800014 | Dnipro | 79044 | Ukraine |
| Investigator site 3800010 | Ivano-Frankivsk | 76008 | Ukraine |
| Investigator site 3800015 | Kharkiv | 61058 | Ukraine |
| Investigator site 3800013 | Kyiv | 21000 | Ukraine |
| Investigator site 380008 | Lutsk | 43024 | Ukraine |
| Investigator site 380009 | Vinnytsia | 21009 | Ukraine |
| Investigator site 3800015 | Vinnytsia | Ukraine |
| Investigator site 3800011 | Zaporizhzhya | 69068 | Ukraine |
| Investigator site 0440017 | Glasgow | United Kingdom |
| Investigator site 0440015 | Inverness | United Kingdom |
| Investigator site 0440026 | London | United Kingdom |
| Investigator site 0440016 | Oxford | United Kingdom |
| Investigator site 0440018 | Sheffield | United Kingdom |
| Investigator site 0440019 | Stoke-on-Trent | United Kingdom |
| Investigator site 0440028 | Tooting | United Kingdom |
| Derived |
| Fisse AL, Schafer E, Hieke A, Schroder M, Klimas R, Brunger J, Huckemann S, Gruter T, Sgodzai M, Schneider-Gold C, Gold R, Nguyen HP, Pitarokoili K, Motte J, Arning L. Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2024 Apr;31(4):e16205. doi: 10.1111/ene.16205. Epub 2024 Jan 11. |
| FG002 | Stage B: Placebo PH20 SC | Participants who completed stage A and received placebo PH20 SC in stage B |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Stage B |
|
|
A total of 322 participants received efgartigimod PH20 SC in Stage A, and 221 of the 322 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. Therefore, the total number of participants was 322, not 543 which was automatically calculated.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Stage A: Efgartigimod PH20 SC | Participants receiving efgartigimod PH20 SC in Stage A |
| BG001 | Stage B: Efgartigimod PH20 SC | Participants who completed stage A and received efgartigimod PH20 SC in stage B |
| BG002 | Stage B: Placebo PH20 SC | Participants who completed stage A and received placebo PH20 SC in stage B |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | A total of 322 participants were enrolled in Stage A. Of those 322, 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. | Count of Participants | Participants |
| ||||||||||
| Age, Continuous | A total of 322 participants were enrolled in Stage A. Of those 322, 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. | Mean | Standard Deviation | years |
| |||||||||
| Sex: Female, Male | A total of 322 participants were enrolled in Stage A. Of those 322, 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. | Count of Participants | Participants |
| ||||||||||
| Ethnicity (NIH/OMB) | A total of 322 participants were enrolled in Stage A. Of those 322, 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. | Count of Participants | Participants |
| ||||||||||
| Race (NIH/OMB) | A total of 322 participants were enrolled in Stage A. Of those 322, 221 participants were randomized in a 1:1 ratio to efgartigimod PH20 SC (N=111) or placebo (N=110) in Stage B. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Number | 95% Confidence Interval | percentage of participants | Up to 12 weeks during the open-label stage A |
|
|
| ||||||||||||||||||||||||||
| Primary | Stage B: Time to First Adjusted INCAT Deterioration Compared to Stage B Baseline | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Median | 95% Confidence Interval | Days | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| |||||||||||||||||||||||||||
| Secondary | Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI) | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Number | 95% Confidence Interval | days | Up to 12 weeks during the open-label stage A |
|
| |||||||||||||||||||||||||||
| Secondary | Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Adjusted INCAT Score | Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability. | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Mean | Standard Deviation | score on a scale | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||
| Secondary | Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Medical Research Council (MRC) Sum Score | The Medical Research Council (MRC) Sum scores range from 0 to 60 with a lower score indicating greater muscle weakness. | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Mean | Standard Error | score on a scale | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||
| Secondary | Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in I-RODS Disability Scores | The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability. | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Mean | Standard Deviation | score on a scale | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||
| Secondary | Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in TUG Score | The Timed Up and Go (TUG) score is calculated as the number of seconds needed to complete a series of actions. The longer time needed to complete this test (expressed in seconds) indicates lower mobility. | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Mean | Standard Error | seconds | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||
| Secondary | Stage A: Change From Stage A Baseline to Last Assessment in Stage A, in Mean Grip Strength | This is measured with a handheld device called a vigometer | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Mean | Standard Deviation | Kilopascal (kPa) | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||
| Secondary | Stage A: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events | Treatment-emergent (serious) AEs expressed in number of events/100 PYFU (participant years of follow-up) | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Number | Events/100 PYFU | Up to 12 weeks during the open-label stage A |
|
| |||||||||||||||||||||||||||
| Secondary | Stage A: Pre-dosing Efgartigimod Serum Concentrations Over Time | The number analyzed in rows decreases due to participants withdrawing from the study and missing participant data. Week 13 was an optional additional week for the confirmation of the ECI. PK-A (Stage A PK analysis set): Participants from the SAF-A for whom at least 1 serum PK concentration during Stage A is available | Posted | Mean | Standard Deviation | ug/mL | Up to 13 weeks during the open-label stage A (12 weeks + optional 1 additional week to confirm evidence of clinical improvement (ECI)) |
|
| |||||||||||||||||||||||||||
| Secondary | Stage A: Percent Changes From Stage A Baseline of Serum IgG Levels Over Time | The number analyzed in rows decreases due to participants advancing to stage B or withdrawing from the study and missing patient data. Week 13 was an optional additional week for the confirmation of the evidence of clinical improvement (ECI). PD-A (Stage A PD analysis set): Participants from the SAF-A for whom at least 1 serum PD concentration during Stage A is available. | Posted | Mean | Standard Error | percent change | Up to 13 weeks during the open-label stage A (12 weeks + optional 1 additional week to confirm evidence of clinical improvement (ECI)) |
|
| |||||||||||||||||||||||||||
| Secondary | Stage A: Number of Participants With Binding Antidrug Antibodies (ADA) Towards Efgartigimod or Antibodies (Ab) Against rHuPH20 and Neutralizing Antibodies (NAb) Against Efgartigimod and/or rHuPH20 | The number of participants analyzed is different since it is based on the number of evaluable participants for each drug. For Ab and NAb against rHuPH20 only 316 participants were evaluable, whereas for ADA and NAb towards efgartigimod 317 participants were evaluable. IMM-A (Stage A immunogenicity analysis set): Participants from the SAF-A for whom at least 1 ADA sample during Stage A is available | Posted | Count of Participants | Participants | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||||
| Secondary | Stage A: Changes From Stage A Baseline to Last Assessment in Stage A, in EQ-5D-5L Visual Analog Scale (VAS) Over Time | Scores range from 0-100 with 100 indicating the best health state. Therefore, positive changes indicate higher health-related quality of life reported by the patient. | SAF-A (Stage A safety analysis set): Participants who received at least 1 dose or part of a dose of efgartigimod PH20 SC in Stage A | Posted | Mean | Standard Error | score on a scale | Up to 12 weeks during the open-label stage A |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Time to CIDP Disease Progression | Time to chronic inflammatory demyelinating polyneuropathy (CIDP) disease progression is defined by the time from first dose of double-blind IMP to the first I-RODS score decrease ≥4 points compared to Stage B baseline using the centile metric. | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Median | 95% Confidence Interval | days | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Number of Participants With Improved Functional Level Compared to Stage B Baseline | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Count of Participants | Participants | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||||
| Secondary | Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in Adjusted INCAT Score | Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) scores range from 0-10 with a score of 10 indicating the greatest degree of disability. | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Mean | Standard Deviation | score on a scale | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in MRC Sum Score | The Medical Research Council (MRC) Sum scores range from 0 to 60 with a lower score indicating greater muscle weakness. | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Mean | Standard Error | score on a scale | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in 24-item I-RODS Disability Score | The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability. | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Mean | Standard Deviation | score on a scale | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in TUG Score | The Timed Up and Go (TUG) score is calculated as the number of seconds needed to complete a series of actions. The longer time needed to complete this test (expressed in seconds) indicates lower mobility. | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Mean | Standard Error | seconds | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Change From Stage B Baseline to Last Assessment in Stage B, in Mean Grip Strength | This is measured with a handheld device called a vigometer | Posted | Mean | Standard Deviation | Kilopascal (kPa) | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| |||||||||||||||||||||||||||
| Secondary | Stage B: Time to 10% Decrease in the 24-item I-RODS | The Inflammatory Rasch-built Overall Disability Scale (I-RODS) score ranges from 0-100, with lower scores indicating the greatest degree of disability. | mITT (modified intent-to-treat) analysis set; Participants who were randomized in Stage B and who received at least 1 dose or part of a dose of IMP in Stage B. | Posted | Median | 95% Confidence Interval | days | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||
| Secondary | Stage B: Exposure Adjusted Occurrence of Treatment-emergent Adverse Events and Serious Adverse Events | Treatment-emergent (serious) AEs expressed in number of events/100 PYFU (participant years of follow-up) | SAF-B (Stage B safety analysis set): Participants from the SCR who received at least 1 dose or part of a dose of IMP in Stage B | Posted | Number | Events/100 PYFU | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| |||||||||||||||||||||||||||
| Secondary | Stage B: Pre-dosing Efgartigimod Serum Concentrations Over Time | The number analyzed in rows decreases due to participants completing the study, withdrawing from the study, and missing participant data. PK-B (Stage B PK analysis set): Participants from the SAF-B for whom at least 1 serum PK concentration during Stage B is available | Posted | Mean | Standard Deviation | ug/mL | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| |||||||||||||||||||||||||||
| Secondary | Stage B: Percent Changes of Serum IgG Levels Over Time | The number analyzed in rows decreases due to participants completing the study, withdrawing from the study, and missing participant data. PD-B (Stage B PD analysis set): Participants from the SAF-B for whom at least 1 serum PD concentration during Stage B is available | Posted | Mean | Standard Error | percent change | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| |||||||||||||||||||||||||||
| Secondary | Stage B: Number of Participants With Binding Antidrug Antibodies (ADA) Towards Efgartigimod or Antibodies (Ab) Against rHuPH20 and Neutralizing Antibodies (NAb) Against Efgartigimod and/or rHuPH20 | IMM-B (Stage B immunogenicity analysis set): Participants from the SAF-B for whom at least 1 ADA sample during Stage B is available | Posted | Number | participants | Up to 48 weeks during the randomized placebo-controlled stage B |
|
| ||||||||||||||||||||||||||||
| Secondary | Stage B: Changes From Stage B Baseline to Last Assessment in Stage B, in EQ-5D-5L Visual Analog Scale (VAS) Over Time | Scores range from 0-100 with 100 indicating the best health state. Therefore, positive changes indicate higher health-related quality of life reported by the patient. | SAF-B (Stage B safety analysis set): Participants from the SCR who received at least 1 dose or part of a dose of IMP in Stage B | Posted | Mean | Standard Error | score on a scale | Up to 48 weeks during the randomized placebo-controlled stage B |
|
|
60 weeks (12 weeks during Stage A and 48 weeks during Stage B)
Adverse events will be assessed at each participant visit. Treatment-emergent adverse events are reported in these tables.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Stage A: Efgartigimod PH20 SC | Participants receiving efgartigimod PH20 SC in stage A | 2 | 322 | 21 | 322 | 60 | 322 |
| EG001 | Stage B: Efgartigimod PH20 SC | Participants who completed stage A and received efgartigimod PH20 SC in stage B | 0 | 111 | 6 | 111 | 31 | 111 |
| EG002 | Stage B: Placebo PH20 SC | Participants who completed stage A and received placebo PH20 SC in stage B | 1 | 110 | 6 | 110 | 15 | 110 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| CARDIAC ARREST | Cardiac disorders | MedDRA 25.1 | Systematic Assessment |
| |
| CLOSTRIDIUM DIFFICILE COLITIS | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| COVID-19 PNEUMONIA | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| SUSPECTED COVID-19 | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| SQUAMOUS CELL CARCINOMA OF SKIN | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 25.1 | Systematic Assessment |
| |
| CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY | Nervous system disorders | MedDRA 25.1 | Systematic Assessment |
| |
| QUADRIPARESIS | Nervous system disorders | MedDRA 25.1 | Systematic Assessment |
| |
| CALCULUS URINARY | Renal and urinary disorders | MedDRA 25.1 | Systematic Assessment |
| |
| DEAFNESS UNILATERAL | Ear and labyrinth disorders | MedDRA 25.1 | Systematic Assessment |
| |
| CHOLELITHIASIS | Hepatobiliary disorders | MedDRA 25.1 | Systematic Assessment |
| |
| APPENDICITIS | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| CONCUSSION | Injury, poisoning and procedural complications | MedDRA 25.1 | Systematic Assessment |
| |
| FOOT FRACTURE | Injury, poisoning and procedural complications | MedDRA 25.1 | Systematic Assessment |
| |
| DEHYDRATION | Metabolism and nutrition disorders | MedDRA 25.1 | Systematic Assessment |
| |
| LIPOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 25.1 | Systematic Assessment |
| |
| PROSTATE CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 25.1 | Systematic Assessment |
| |
| TRANSITIONAL CELL CARCINOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 25.1 | Systematic Assessment |
| |
| URETHRAL STENOSIS | Renal and urinary disorders | MedDRA 25.1 | Systematic Assessment |
| |
| URINARY BLADDER POLYP | Renal and urinary disorders | MedDRA 25.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| INJECTION SITE ERYTHEMA | General disorders | MedDRA 25.1 | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA 25.1 | Systematic Assessment |
| |
| INJECTION SITE BRUISING | General disorders | MedDRA 25.1 | Systematic Assessment |
| |
| COVID-19 | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
| |
| UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | MedDRA 25.1 | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Regulatory manager | Argenx | Please email: | regulatory@argenx.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 9, 2023 | May 2, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D020277 | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating |
| ID | Term |
|---|---|
| D011129 | Polyradiculoneuropathy |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D011115 | Polyneuropathies |
| D010523 | Peripheral Nervous System Diseases |
| D009468 | Neuromuscular Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| Death |
|
| Lack of Efficacy |
|
| Lost to Follow-up |
|
| Prohibited medications |
|
| Protocol Violation |
|
| Sponsor decision |
|
| Withdrawal by Subject |
|
| Other |
|
|
| Stage B |
|
|
|
| Stage B |
|
|
|
| Stage B |
|
|
|
| Stage B |
|
|
|
| Stage B |
|
|
|
|
| Title | Denominators | Categories |
|---|
| 25th percentile |
| |||||
| 50th percentile (median) |
| |||||
| 75th percentile |
|
|
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| dominant hand |
| |||||
| nondominant hand |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Between 18 and 65 years |
|
| >=65 years |
|
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|